[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-dysfunction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,83,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644724","ulinastatin-on-systemic-immune-inflammation-in-patients-with-complicated-intra-abdominal-infection-100644724",false,"NCT07672496","Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection","A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection","UTI-cIAI","Inclusion Criteria:\n\n1. Able to provide written informed consent voluntarily.\n2. Age ≥ 18 years old, any gender.\n3. Diagnosed with severe complicated intra-abdominal infection (cIAI) within 48 hours, consistent with the 2025 expert consensus for cIAI diagnosis. Diagnosis is confirmed by clinical symptoms (fever, abdominal pain, distension, etc.), abdominal imaging (CT\u002Fultrasound\u002FMRI), intraoperative findings, or positive pathogen culture of abdominal drainage fluid.\n4. Baseline Sequential Organ Failure Assessment (SOFA) score ≥ 2 points.\n\nExclusion Criteria:\n\n1. Severe immune deficiency conditions, including AIDS, prior solid organ or bone marrow transplantation, HIV infection with CD4 count \\\u003C 200 cells\u002Fmm³, long-term high-dose glucocorticoid therapy (prednisone \\> 20 mg\u002Fday), ongoing chemotherapy for malignant tumors, or absolute neutrophil count \\\u003C 1000 cells\u002Fmm³.\n2. Severe irreversible underlying diseases, including chronic renal failure requiring dialysis, Child-Pugh grade C liver disease, liver disease with severe portal hypertension, or acute liver failure.\n3. Patients with active malignant tumors, pregnancy, or severe psychiatric disorders.\n4. American Society of Anesthesiologists (ASA) physical status grade IV or above.\n5. Severe coagulation disorder defined as ISTH-DIC score ≥ 5 points.\n6. Critically ill patients with expected death within 48 hours after admission.\n7. Known allergy to ulinastatin or any ingredients of the study preparation.\n8. Any condition that, in the judgment of the principal investigator, makes the patient inappropriate for trial participation.","ALL","18 Years",{"count":20,"type":21},165,"ESTIMATED","INTERVENTIONAL",[24],"NA","Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk. Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear. This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (≥18 years, SOFA≥2) at Fujian Medical University Union Hospital. Eligible patients are randomized into low-dose ulinastatin, high-dose ulinastatin and normal saline placebo groups (1:1:1, 5 days intravenous treatment plus standard care), total planned enrollment 165 participants after 10% dropout adjustment. Primary endpoint is Day5 change of Systemic Immune-Inflammation Index (SII); secondary outcomes include serial inflammatory biomarkers, SOFA variation, organ dysfunction, hospitalization duration, 28-day mortality and safety profiles. This pilot aims to clarify ulinastatin's immune-modulating effect and inform future large RCT design.",[27,28,29,30],"Complicated Intra-abdominal Infection (cIAI)","Systemic Inflammatory Response","Sepsis","Immune Dysfunction",[32,33,34,35,36],"immune dysfunction","Complicated intra-abdominal infection","Ulinastatin","SII","inflammation","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":21},"2026-10-30",{"date":45,"type":21},"2028-06-30",{"name":47,"class":48},"Fujian Medical University Union Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100596078","natural-history-of-type-1-interferonopathies-insights-from-a-european-cohort-100596078","NCT07040774","Natural History of Type 1 Interferonopathies: Insights From a European Cohort","EU-IFNp","Inclusion Criteria:\n\n* Genetically confirmed patient with type I interferonopathy\n* Patient affiliated to a social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n\\- Opposition of the patient and\u002For parental authority if the patient is a minor, to participation in the study.",{"count":58,"type":21},500,"OBSERVATIONAL","Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.\n\nNearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.\n\nIn this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.\n\nThe main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.\n\nThe overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.",[62,30,63,64],"Genetic Disease","Neurological Diseases or Conditions","Autoimmune Diseases",[66,67,68,69,70,71],"Immune dysfuntion","Neurological disease","Autoimmune diseases","Genetics diseases","Interferon","Aicardi-Goutieres Syndrom","RECRUITING","2026-05-12",{"date":75,"type":41},"2026-05-13",{"date":77,"type":41},"2025-10-01",{"date":79,"type":21},"2045-10",{"name":81,"class":48},"Imagine Institute",32,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":59,"phases":4,"briefSummary":95,"conditions":96,"keywords":103,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100636173","project-phoenix-molecular-signatures-of-burn-pit-exposure-100636173","NCT07562243","Project PHOENIX: Molecular Signatures of Burn Pit Exposure","Molecular, Genomic, Cellular, and Functional Characterization of Blood Specimens From Former U.S. Service Members With Prior Burn Pit Exposure","PHOENIX","Inclusion Criteria:\n\n* Age 18 years or older at the time of consent\n* Former or current U.S. Service Member, including Active Duty, Reserve, National Guard, or Veteran status\n* For exposed cohort: prior deployment to a location with known burn pit operations, based on participant report and available confirmation when feasible\n* For control cohort: no known deployment to burn pit locations\n* Able and willing to provide informed consent and HIPAA authorization\n* Willing to complete study questionnaires and donate venous blood sample\n* Able to complete study procedures in English or with approved translation support\n* Available for one baseline visit and optional future re-contact, if applicable\n\nExclusion Criteria:\n\n* Active serious illness or infection that, in the investigator's judgment, would compromise participation or specimen integrity\n* Receipt of systemic chemotherapy, immunotherapy, or radiation therapy within the past 6 months\n* High-dose systemic immunosuppression, defined as more than 20 mg prednisone equivalent daily for more than 14 days within the past 3 months\n* Pregnant or currently breast-feeding\n* Hemoglobin less than 10 g\u002FdL, known bleeding disorder, or platelet count less than 100 × 10\\^9\u002FL, if known\n* Severe psychiatric illness or other condition that impairs ability to provide informed consent\n* Prisoner or institutionalized individual\n* Prior participation in this or a related Project PHOENIX protocol\n* Any other condition that, in the investigator's judgment, may increase risk or interfere with study conduct or data integrity",true,{"count":93,"type":21},1000,"5 Years","Project PHOENIX is an observational clinical research study designed to characterize molecular, genomic, cellular, and functional features in blood specimens from former U.S. Service Members with prior burn pit exposure and from matched unexposed controls. Participants will complete screening, informed consent, health and exposure questionnaires, and a one-time blood collection. Blood-derived specimens may undergo genomic, epigenomic, transcriptomic, proteomic, metabolomic, immunophenotyping, and cellular functional analyses. Participants may also agree to optional future re-contact for health updates and possible repeat blood collection. The goal is to identify biologic signatures associated with prior deployment-related burn pit exposure and to support future biomarker discovery and translational research in veteran health.",[97,98,99,100,101,30,102],"Burn Pit Exposure","Airborne Hazard Exposure","Veteran Health","Deployment-Related Toxic Exposure","Biomarkers","Respiratory Symptoms",[104,105,106,107,108,109,110,111,112,113,114,115,116],"Burn pit","Airborne hazards","Veterans","Deployment exposure","Multi-omics","PBMC","Biomarker discovery","Transcriptomics","Epigenomics","Proteomics","Metabolomics","Toxic exposure","Military service","2026-04-27",{"date":119,"type":41},"2026-05-01",{"date":119,"type":21},{"date":122,"type":21},"2031-12-31",{"name":124,"class":125},"Creative Medical Technology Holdings Inc","INDUSTRY",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":49},"100534188","genotype-phenotype-characterization-study-on-genetic-diseases-with-immune-and-neurological-dysfunctions-100534188","NCT06235580","Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions","IFN","Inclusion criteria\n\n* Patients :\n\n  * Have \u002F present a family history of genetic disease with immune and neurological dysfunction.\n  * Have signed an informed consent form.\n* Unaffected related subjects :\n\n  * Be related to a patient included in this research.\n  * Have signed an informed consent form.\n* Control patients\n\n  * Be free of any genetic disease with immune and neurological dysfunction.\n  * Have undergone surgery as part of their management\n  * Have signed an informed consent form.\n\nNon-inclusion criteria\n\n✓ Be deprived of liberty",{"count":93,"type":21},"Over the past twenty years, Prof. Yanick Crow and his team have developed internationally recognized expertise in genetic pathologies affecting the immune and neurological systems. The pathologies studied have a particularly severe impact on patients' quality of life, with a high mortality rate and a significant risk of occurrence in affected families. These pathologies are rare, and very often under-diagnosed. To date, there is virtually no effective curative treatment.\n\nProf. Crow's team operates at the frontier between clinical and research work, and from experience, the team knows that patients and families affected by these serious pathologies are often highly motivated to help research into the pathology that affects them.\n\nInitially, Prof. Crow's research focused primarily on the study of the genetic disease Aicardi-Goutières Syndrome (AGS). However, there is an undeniable clinical and pathological overlap between AGS and other forms of disease such as autoimmune systemic lupus erythematosus and many other genetic pathologies - e.g. familial lupus engelure, spondyloenchondromatosis and COPA syndrome. This is why research is being extended to all genetic diseases with immune and neurological dysfunctions.",[136,30,137,64],"Genetic Diseases","Neurological Disease","2025-12-12",{"date":140,"type":41},"2025-12-19",{"date":142,"type":41},"2015-12-28",{"date":144,"type":21},"2035-12-27",{"name":81,"class":48}]